Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma

Beverly A. Teicher, Ying Nan Chen, Gulshan Ara, Yasunori Emi, Yoshihiro Kakeji, Yoshihiko Maehara, Susan Keyes, David Northey

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Interleukin-11 (rhIL-11) is a cytokine that has been shown to enhance the recovery of bone marrow and intestinal crypt cells after cytotoxic insult with radiation or anticancer drugs. The current study examined the effects of rhIL-11 on the response of CEM human lymphoblastic leukemia cells and on the EMT-6 murine mammary carcinoma in vivo to cytotoxic anticancer therapies. Exposure of CEM cells to rhIL-11 for 24 hr did not alter the cytotoxicity of melphalan or radiation, increased the cytotoxicity of CDDP (100 μM) and 4-hydroperoxycyclophosphamide (50 βM) and decreased the cytotoxicity of 5-fluorouracil and ara-C toward the cells. Treatment of mice bearing the EMT-6 tumor with rhIL-11 twice daily for 4 days prior to and the day of cytotoxic therapy resulted in no significant change in the tumor cell killing or bone marrow CFU-GM killing by melphalan, cyclophosphamide, thiotepa, CDDP, radiation, 5-fluorouracil or ara-C. Administration of rhIL-11 twice per day on days 7-18 to EMT-6 tumor bearing animals receiving high dose chemotherapy (melphalan, thiotepa or cyclophosphamide) as a single dose on day 7 followed by mobilized peripheral blood cells on day 8 and rhG-CSF on days 8-20, tended to prolong the tumor growth delay produced by the drugs. This rhIL-11 treatment also resulted in a move rapid recovery of white blood cells and granulocytes in the animals. Furthermore, animals treated with rhIL-11 had improved survival rates compared with animals receiving all other normal tissue support without rhIL-11.

Original languageEnglish
Pages (from-to)864-870
Number of pages7
JournalInternational Journal of Cancer
Volume67
Issue number6
DOIs
Publication statusPublished - Oct 30 1996

Fingerprint

oprelvekin
Interleukin-11
Breast Neoplasms
Melphalan
Thiotepa
perfosfamide
Cytarabine
Therapeutics
Radiation
Fluorouracil
Cyclophosphamide
Neoplasms
Bone Marrow
Granulocyte-Macrophage Progenitor Cells
In Vitro Techniques
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Granulocytes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma. / Teicher, Beverly A.; Chen, Ying Nan; Ara, Gulshan; Emi, Yasunori; Kakeji, Yoshihiro; Maehara, Yoshihiko; Keyes, Susan; Northey, David.

In: International Journal of Cancer, Vol. 67, No. 6, 30.10.1996, p. 864-870.

Research output: Contribution to journalArticle

Teicher, Beverly A. ; Chen, Ying Nan ; Ara, Gulshan ; Emi, Yasunori ; Kakeji, Yoshihiro ; Maehara, Yoshihiko ; Keyes, Susan ; Northey, David. / Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma. In: International Journal of Cancer. 1996 ; Vol. 67, No. 6. pp. 864-870.
@article{ece75728845c44b2b2fb42b367886147,
title = "Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma",
abstract = "Interleukin-11 (rhIL-11) is a cytokine that has been shown to enhance the recovery of bone marrow and intestinal crypt cells after cytotoxic insult with radiation or anticancer drugs. The current study examined the effects of rhIL-11 on the response of CEM human lymphoblastic leukemia cells and on the EMT-6 murine mammary carcinoma in vivo to cytotoxic anticancer therapies. Exposure of CEM cells to rhIL-11 for 24 hr did not alter the cytotoxicity of melphalan or radiation, increased the cytotoxicity of CDDP (100 μM) and 4-hydroperoxycyclophosphamide (50 βM) and decreased the cytotoxicity of 5-fluorouracil and ara-C toward the cells. Treatment of mice bearing the EMT-6 tumor with rhIL-11 twice daily for 4 days prior to and the day of cytotoxic therapy resulted in no significant change in the tumor cell killing or bone marrow CFU-GM killing by melphalan, cyclophosphamide, thiotepa, CDDP, radiation, 5-fluorouracil or ara-C. Administration of rhIL-11 twice per day on days 7-18 to EMT-6 tumor bearing animals receiving high dose chemotherapy (melphalan, thiotepa or cyclophosphamide) as a single dose on day 7 followed by mobilized peripheral blood cells on day 8 and rhG-CSF on days 8-20, tended to prolong the tumor growth delay produced by the drugs. This rhIL-11 treatment also resulted in a move rapid recovery of white blood cells and granulocytes in the animals. Furthermore, animals treated with rhIL-11 had improved survival rates compared with animals receiving all other normal tissue support without rhIL-11.",
author = "Teicher, {Beverly A.} and Chen, {Ying Nan} and Gulshan Ara and Yasunori Emi and Yoshihiro Kakeji and Yoshihiko Maehara and Susan Keyes and David Northey",
year = "1996",
month = "10",
day = "30",
doi = "10.1002/(SICI)1097-0215(19960917)67:6<864::AID-IJC17>3.0.CO;2-1",
language = "English",
volume = "67",
pages = "864--870",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma

AU - Teicher, Beverly A.

AU - Chen, Ying Nan

AU - Ara, Gulshan

AU - Emi, Yasunori

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

AU - Keyes, Susan

AU - Northey, David

PY - 1996/10/30

Y1 - 1996/10/30

N2 - Interleukin-11 (rhIL-11) is a cytokine that has been shown to enhance the recovery of bone marrow and intestinal crypt cells after cytotoxic insult with radiation or anticancer drugs. The current study examined the effects of rhIL-11 on the response of CEM human lymphoblastic leukemia cells and on the EMT-6 murine mammary carcinoma in vivo to cytotoxic anticancer therapies. Exposure of CEM cells to rhIL-11 for 24 hr did not alter the cytotoxicity of melphalan or radiation, increased the cytotoxicity of CDDP (100 μM) and 4-hydroperoxycyclophosphamide (50 βM) and decreased the cytotoxicity of 5-fluorouracil and ara-C toward the cells. Treatment of mice bearing the EMT-6 tumor with rhIL-11 twice daily for 4 days prior to and the day of cytotoxic therapy resulted in no significant change in the tumor cell killing or bone marrow CFU-GM killing by melphalan, cyclophosphamide, thiotepa, CDDP, radiation, 5-fluorouracil or ara-C. Administration of rhIL-11 twice per day on days 7-18 to EMT-6 tumor bearing animals receiving high dose chemotherapy (melphalan, thiotepa or cyclophosphamide) as a single dose on day 7 followed by mobilized peripheral blood cells on day 8 and rhG-CSF on days 8-20, tended to prolong the tumor growth delay produced by the drugs. This rhIL-11 treatment also resulted in a move rapid recovery of white blood cells and granulocytes in the animals. Furthermore, animals treated with rhIL-11 had improved survival rates compared with animals receiving all other normal tissue support without rhIL-11.

AB - Interleukin-11 (rhIL-11) is a cytokine that has been shown to enhance the recovery of bone marrow and intestinal crypt cells after cytotoxic insult with radiation or anticancer drugs. The current study examined the effects of rhIL-11 on the response of CEM human lymphoblastic leukemia cells and on the EMT-6 murine mammary carcinoma in vivo to cytotoxic anticancer therapies. Exposure of CEM cells to rhIL-11 for 24 hr did not alter the cytotoxicity of melphalan or radiation, increased the cytotoxicity of CDDP (100 μM) and 4-hydroperoxycyclophosphamide (50 βM) and decreased the cytotoxicity of 5-fluorouracil and ara-C toward the cells. Treatment of mice bearing the EMT-6 tumor with rhIL-11 twice daily for 4 days prior to and the day of cytotoxic therapy resulted in no significant change in the tumor cell killing or bone marrow CFU-GM killing by melphalan, cyclophosphamide, thiotepa, CDDP, radiation, 5-fluorouracil or ara-C. Administration of rhIL-11 twice per day on days 7-18 to EMT-6 tumor bearing animals receiving high dose chemotherapy (melphalan, thiotepa or cyclophosphamide) as a single dose on day 7 followed by mobilized peripheral blood cells on day 8 and rhG-CSF on days 8-20, tended to prolong the tumor growth delay produced by the drugs. This rhIL-11 treatment also resulted in a move rapid recovery of white blood cells and granulocytes in the animals. Furthermore, animals treated with rhIL-11 had improved survival rates compared with animals receiving all other normal tissue support without rhIL-11.

UR - http://www.scopus.com/inward/record.url?scp=0029911370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029911370&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960917)67:6<864::AID-IJC17>3.0.CO;2-1

DO - 10.1002/(SICI)1097-0215(19960917)67:6<864::AID-IJC17>3.0.CO;2-1

M3 - Article

C2 - 8824560

AN - SCOPUS:0029911370

VL - 67

SP - 864

EP - 870

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -